The Alliance for Clinical Trials in Oncology Foundation, a nonprofit organization that supports the mission to reduce the impact of cancer,.
The Alliance for Clinical Trials in Oncology Foundation, a nonprofit organization that supports the mission to reduce the impact of cancer, has selected Oracle’s Siebel Clinical Trial Management System and Oracle Health Sciences IRT as the IT platform for a comprehensive, 10-year clinical study, conducted in partnership with a tier-one pharmaceutical company and sponsored by Alliance Foundation Trials (AFT). AFT will use Siebel Clinical Trial Management System and plans to create a centralized trial management database that provides users with the most relevant information based on their specific roles and responsibilities and is designed to speed access to critical data, improve monitoring and patient safety, and keep data secure. Users can also access the system via any browser from any device, further elevating productivity and the user experience. The deployment of Oracle Health Sciences IRT is designed to enable AFT to more effectively manage patient randomization and global supply chains by extending interactive voice response (IVR) and interactive web response (IWR) systems.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.